RU2078590C1 - Method for treatment of chronic prostatitis - Google Patents

Abstract

FIELD: medicine, urology. SUBSTANCE: patients affected with chronic prostatitis are treated by administering under capsule of both lobes of prostate gland suspension of viable Leipig cells taken from embryonal-origin mammals and newborn infants in dose of at least 2 min cells per 1 ml. EFFECT: effective cure for people suffering from chronic prostatitis.

Description

 The invention relates to medicine and for the treatment of patients with chronic prostatitis.

 Chronic prostatitis is one of the most common diseases currently in men of reproductive age (18-55 years old). According to medical statistics from the last decade, the presence of chronic prostatitis is noted in at least 40% of men. In some areas, higher (up to 70%) indicators are also known. The growth trend of this disease is associated with many factors: economic instability, bad habits, low sexual culture, the growth of sexually transmitted diseases, illiterate and uncontrolled use of drugs.

 Chronic prostatitis can lead to various and serious complications, for example, chronic renal failure, impaired sexual function and infertility in men, which in turn leads to severe disorders of the nervous system and mental disorders of patients.

 The tactics of treating chronic prostatitis is to find out the causes of this disease, to eliminate the present infectious agent, or to eliminate the negative factors that affect the development of the disease. If the elimination of the pathological microbial flora of the prostate gland is not particularly difficult, then the restoration of the normal function of the prostate gland requires a long diverse treatment, which does not always end with a complete cure. A known method of treatment by direct injection of a drug into the tissue of the prostate gland (antibiotics, corticosteroids, amniocenes, synthetic androgens). The method gives a short-term effect and is fraught with the possibility of developing complications (sclerosis of the vascular tissue of the gland, inflammation of the surrounding fiber).

 The aim of the invention is the possibility of using Leydig cells of mammals (embryonic and newborns) in the treatment of chronic prostatitis by transplantation. This goal was achieved by introducing a suspension of viable Leydig cells under the capsule of both prostate glands.

 The essence of the proposed method is as follows. A suspension of viable Leydig-interstitial cells of testicles of human, cow, pig, and also newborn piglets and calves is prepared beforehand. Newborn individuals should be as young as possible so that stable antigenic species specificity does not have time to take shape. To prepare the suspension, solutions are used that contain a nutrient substrate for the cells, in particular, the compositions of standard media for cells of animal tissue — Eagle’s media, Hanks’s solutions, medium 199 and the like. The desired density of the suspension is at least 2 million cells in 1 ml. All procedures for the preparation of the suspension should be carried out under aseptic conditions, and the suspension itself must be sterile. Under local anesthesia of the perineal region, for example, using chloroethyl, with palpation of the prostate, the suspension is administered under the capsule of both prostate glands. The effective dose has an order of at least 2 million cells. It is advisable to administer this dose in a volume not exceeding 1 ml, so as not to cause excessive tissue trauma and pain. The treatment procedure is technically easy and can be performed on an outpatient basis. The method is acceptable in the absence of acute inflammatory phenomena in the prostate gland. Subject to aseptic measures, it gives no complications.

 The prostate, being a hormone-dependent organ, is directly related to the function of the testes, whose interstitial hormone producers are Leydig cells. Chronic prostatitis causes a violation of the synthesis of androgens, which leads to atrophy of the testicular epithelium, an increase in the proportion of inactive Leydig cells and the prevalence of estrogens over androgens, which in turn sharply reduces the functional activity of the prostate gland, slowing down all intragranular biosynthetic processes and causing death of the glandular epithelium. The problem of the emerging "vicious circle": chronic prostatitis androgenic dysfunction is largely solved by the proposed method.

 The experimental data allow us to conclude that in almost all cases, Leydig cells injected under the capsule of both lobes of the gland give a sharply positive effect, enhancing the functional abilities of glandular tissue.

 The effectiveness of the proposed method was confirmed by clinical experiments on volunteers. In clinical trials on volunteers, patients 5-7 days after treatment with the method of transplantation of viable Leydig cells noted a significant improvement in the condition, the disappearance of pain in the perineum, the absence of dysuric phenomena, the appearance of spontaneous and adequate erections.

 Example 1. Patient P. 30 years old, medical history N 2733, was admitted to the Center for Human Reproduction 4. o7.94 with complaints of aching pain in the sacrum, perineum and scrotum. The disease began in 1988, after suffering nonspecific urethritis. Periodically, 2-3 times a year, exacerbations of the disease occurred, manifested by increased pain, increased urination. According to the available medical documents, the patient has been diagnosed with chronic prostatitis since 1988. Once or twice a year, courses of antibacterial, anti-inflammatory treatment were carried out, which did not lead to persistent remission or recovery.

 An objective examination of any pathological abnormalities from the external genitalia and rectum was not detected, with the exception of moderate enlargement, edema and severe tenderness of the prostate gland during rectal digital examination. Microscopic examination of the secretion of the prostate determined up to 15 leukocytes in the SC and a small amount of lecithin grains. A bacterial study of the backstage and the study of scraping from the urethra on chlamydia, mycoplasma, ureaplasma and the herpes simplex virus were not detected. General clinical analysis of urine without pathological changes. Ultrasound examination of the bladder and prostate revealed an increase in the prostate to 4.8x4.5x4.2, heterogeneity of its structure.

 On July 8, 94, transperitoneal puncture access, under general anesthesia, performed xenograft of a live Leydig cell culture under a capsule of the prostate gland in both its lobes.

 In the next 8 days after transplantation, the patient noted the disappearance of pain. In satisfactory condition, was discharged under the supervision of a urologist at the place of residence.

 During the control examinations in September and November 1994, the observed did not show any complaints. According to a study of the prostate of general consistency and size, it is painless. According to the results of a microscopic examination of the secretion, prostate leukocytes are single in the microscope, an abundance of lecithin grains.

 July 7, 1995 there are no complaints during the follow-up examination, the results of the examination and laboratory tests are normal.

 2. Patient L., 29 years old, medical history No. 1740, was admitted to the Center for Human Reproduction of the Ministry of Health of the Russian Federation on April 22, 94 with complaints of dull pain in the perineum and suprapubic region, aggravated after drinking alcohol, spicy food, and hypothermia. The disease is three years old.

 Previous treatment, on an outpatient basis and in a hospital setting, did not lead to improvement.

 An objective study found a slight increase, decreased tone and tenderness of the prostate. Microscopic examination of the secretion of the prostate gland revealed a decrease in the number of lecithin grains to 5-8 leukocytes in the field of view of the microscope; in the ejaculate 10-12 leukocytes in the s / s. Other deviations with objective and additional research methods were not determined.

 04/25/94, puncture access through the perineum, with digital control from the rectum, performed xenograft live culture of Leydig cells under the capsule of the prostate in both its lobes.

 Control studies performed in July and October 1994 did not reveal any pathological changes in the prostate gland. Microscopy of prostate secrets revealed a significant amount of lecithin grains.

 Control 05/29/95 without pathology.

 3. Patient G. 32 years old, medical history N 1979, was admitted to the Center for Human Reproduction of the Ministry of Health of the Russian Federation 05/12/94. On admission, he complained of persistent pain in the suprapubic region and the scrotum. The disease began in 1990, with annual exacerbations. According to the outpatient card, the treatment had only a temporary effect (up to 1.0-1.5 months).

 A digital rectal examination revealed edema and severe tenderness of the prostate gland. Ultrasound examination of the prostate determined the heterogeneity of the structure. Microscopic examination of the secretion of the prostate: the crystallization phenomenon is impaired, white blood cells are 8-10 in p / s. Lecithin grains are single: microflora is absent.

 Conducted anti-inflammatory and physiotherapeutic treatment was not successful. On May 27, 94, a xenograft of a live Leydig cell culture was performed under a capsule of the prostate gland, by injection through the perineum in both lobes. Observation of the patient within 10 days after transplantation indicated the disappearance of pain. Subsequent examinations of the patient in December 1994 did not reveal any abnormalities in the state of the prostate gland. A large number of lecithin grains and the absence of leukocytes were found in the secretion of the prostate; the phenomenon of crystallization of the secret was restored.

 Control 1.06.95 g. Without pathology.

 A single implantation of Leydig cells provides a lasting effect for 1 year (observation period). An analysis of the patent and scientific and technical literature showed that there is no information on the use of Leydig cells for the successful treatment of chronic prostatitis in humans and the applicant therefore believes that the proposed method meets the requirements of the invention.

Claims (1)

 A method of treating chronic prostatitis by introducing a drug under a capsule of both prostate glands, characterized in that a suspension of viable mammalian Leydig cells at a dose of at least 2 million cells per ml is used as a medicine.